加载中...

Vertex Pharmaceuticals Incorporated (VRTX) 财务分析 | 估值·财报 | 100Baggers.club

Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

加载图表中...

加载图表中...

📊 估值

关键估值指标

EV/EBITDA (TTM)

i

Enterprise Value, EBITDA and Ratio

EV/EBIT (TTM)

i

Enterprise Value, EBIT and Ratio

EV/Sales (TTM)

i

Enterprise Value, Revenue and Ratio

P/E Ratio (TTM)

i

Market Cap, Net Income and Ratio

P/B Ratio (Quarterly)

i

Market Cap, Book Value and Ratio

FCF Yield (TTM)

i

FCF, Enterprise Value and Yield

PR Profit Ratio (PPM)

i

PE Ratio, ROE and Profit Ratio (PR = PE / ROE)

📈 成长

营收、盈利和每股成长指标

Revenue (Quarterly)

i

Quarterly Revenue

Revenue/Share (Quarterly)

i

Revenue Per Share

Net Income (Quarterly)

i

Quarterly Net Income

EPS (Quarterly)

i

Earnings Per Share

Gross Profit/Share (Quarterly)

i

Gross Profit Per Share

OCF/Share (Quarterly)

i

Operating Cash Flow Per Share

FCF/Share (Quarterly)

i

Free Cash Flow Per Share

Operating Leverage (YoY)

i

Change in Operating Income / Change in Revenue

💰 盈利

利润率和净资产收益率

Gross Margin (TTM)

i

Revenue, Gross Profit and Gross Margin

Operating Margin (TTM)

i

Revenue, Operating Income and Operating Margin

Net Profit Margin (TTM)

i

Revenue, Net Income and Net Profit Margin

ROE (TTM)

i

Equity, Net Income and Return on Equity

ROA (TTM)

i

Assets, Net Income and Return on Assets

ROTCE - Return on Tangible Common Equity (TTM)

i

Net Income, Tangible Common Equity and ROTCE

OCF Margin (TTM)

i

Revenue, Operating Cash Flow and OCF Margin

FCF Margin (TTM)

i

Revenue, Free Cash Flow and FCF Margin

💵 现金质量

现金流质量和转换指标

OCF/NI Ratio (TTM)

i

Operating Cash Flow, Net Income and Ratio

FCF/NI Ratio (TTM)

i

Free Cash Flow, Net Income and Ratio

OCF/Capex (TTM)

i

Operating Cash Flow, Capex and Coverage Ratio

OCF/SBC (TTM)

i

Operating Cash Flow, SBC and Coverage Ratio

🛡️ 财务韧性

债务、流动性和财务健康度

Debt/Equity (quarterly)

i

Total Debt, Total Equity and Debt/Equity Ratio

EBITDA/Net Debt (TTM)

i

EBITDA, Net Debt and Coverage Ratio

Interest Coverage (TTM)

i

EBIT, Interest Expense and Coverage Ratio

Current Ratio (quarterly)

i

Current Assets, Current Liabilities and Current Ratio

Quick Ratio (quarterly)

i

Quick Assets, Current Liabilities and Quick Ratio

Altman Z-Score

i

Financial Distress Prediction Model

⚙️ 运营与资本效率

资产利用率、营运资本、ROIC和资本效率

ROIC (TTM)

i

NOPAT, Invested Capital and Return on Invested Capital

ROCE - Return on Capital Employed (TTM)

i

EBIT, Capital Employed and Return on Capital Employed

Asset Turnover (TTM)

i

Revenue, Total Assets and Turnover Ratio

CapEx/Depreciation - Investment Intensity (TTM)

i

CapEx, Depreciation and Ratio (>1=Expansion, <1=Contraction)

R&D/Gross Profit - R&D Intensity (TTM)

i

R&D Expenses, Gross Profit and Ratio

SG&A/Revenue - SG&A Efficiency (TTM)

i

SG&A Expenses, Revenue and Ratio

Cash Conversion Cycle (TTM)

i

DSO + DIO - DPO (in days)

DSO - Days Sales Outstanding (TTM)

i

Average Receivables and Days Sales Outstanding

DIO - Days Inventory Outstanding (TTM)

i

Average Inventory and Days Inventory Outstanding

DPO - Days Payables Outstanding (TTM)

i

Average Payables and Days Payables Outstanding

Goodwill/Assets (Quarterly)

i

Goodwill as % of Total Assets

🎁 股东回报

股息、股票回购、稀释和内部人交易活动

Dividend Yield (TTM)

i

Dividend Per Share, Share Price and Dividend Yield

Buyback Yield (TTM)

i

Net Buyback and Buyback Yield

Buyback Yield (3 Years)

i

Net Buyback 3Y and Buyback Yield 3Y

Dilution Rate (1 Year)

i

Current Shares, 1Y Ago Shares and Dilution Rate

Dilution Rate (3 Years)

i

Current Shares, 3Y Ago Shares and Dilution Rate

SBC Offset Rate (TTM)

i

Buyback / Stock-Based Comp and SBC Ratio

Insider Activity Rate (TTM)

i

Insider Net Buying and Activity Rate

利润瀑布图分析

加载图表中...

P

盈利能力指标

Gross Profit Margini毛利率

86.85%

毛利润 = $2.59B

营业收入 = $2.99B

Operating Profit Margini营业利润率

38.10%

营业利润 = $1.14B

营业收入 = $2.99B

EBITDA MarginiEBITDA利润率

38.10%

EBITDA = $1.14B

营业收入 = $2.99B

EBIT MarginiEBIT利润率

38.10%

EBIT = $1.25B

营业收入 = $2.99B

Net Profit Margini净利率

34.53%

净利润 = $1.03B

营业收入 = $2.99B

Pretax Profit Margini税前利润率

41.95%

税前利润 = $1.25B

营业收入 = $2.99B

E

运营效率指标

Interest Coveragei利息保障倍数

488.09x

EBIT (TTM) = $5.03B

利息费用 (TTM) = $0.01B

-11.9x

258.3x

348.6x

347.6x

488.1x

SG&A / Revenuei销管费率

16.53%

销售及管理费用 = $0.49B

营业收入 = $2.99B

R&D / Revenuei研发占比

32.19%

研发费用 = $0.96B

营业收入 = $2.99B

R

回报率指标 (TTM)

ROAi总资产回报率

17.58%

净利润 = $4.34B

平均总资产 = $24.68B

ROEi净资产收益率

24.20%

净利润 = $4.34B

平均股东权益 = $17.93B

ROICi投入资本回报率

52.99%

NOPAT (TTM) = $4.01B

平均投入资本 = $7.57B

(NOPAT = 营业利润 × (1 - 有效税率))

(平均投入资本 = (本期IC + 去年同期IC) / 2)

Revenue Growthi营收增长率

7.82%

当期营收 = $2.99B

去年同期营收 = $2.77B

+3.1%

+12.1%

+11.0%

+10.8%

+7.8%

Operating Cash Flow/Sharei每股经营现金流

$16.55

经营现金流 = $4.24B

流通股数 = 0.26B

$-3.78

$14.86

$14.43

$14.18

$16.55

综合分析

利润表项目	同比增长	当季数据	趋势
营业收入	+7.8%	$2.99B	↑
毛利	+7.8%	$2.59B, 86.85%	↑
营业利润	+80.6%	$1.14B, 38.10%	↑
EBITDA	+45.6%	$1.14B, 38.10%	↑
税前利润	+71.5%	$1.25B, 41.95%	↑
净利润	+59.6%	$1.03B, 34.53%	↑
稀释每股收益	+61.4%	4.02	↑

加载图表中...

L

流动性指标

Current Ratioi流动比率

3.02

健康

流动资产 = $11.73B

流动负债 = $3.88B

Quick Ratioi速动比率

2.57

健康

速动资产 = $9.96B

流动负债 = $3.88B

Cash Ratioi现金比率

1.87

健康

现金及等价物 = $7.25B

流动负债 = $3.88B

Cash Ratio = (Cash + Short-term Investments) / Current Liabilities

L

杠杆指标

Debt to Equityi债务权益比

0.10

健康

总债务 = $1.99B

总权益 = $19.36B

Liabilities to Assetsi资产负债率 (总负债)

26.9%

健康

总负债 = $7.12B

总资产 = $26.48B

Equity Multiplieri权益乘数

1.37

健康

总资产 = $26.48B

总权益 = $19.36B

E

效率指标

Asset Turnoveri总资产周转率

0.50

关注

营收 (TTM) = $12.26B

平均总资产 = $24.68B

Inventory Turnoveri存货周转率

0.97

关注

营业成本 (TTM) = $1.68B

平均存货 = $1.73B

Receivables Turnoveri应收账款周转率

6.05

正常

营收 (TTM) = $12.26B

平均应收账款 = $2.02B

S

偿债能力

Interest Coveragei利息保障倍数

488.09

健康

EBIT (TTM) = $5.03B

利息费用 (TTM) = $0.01B

Net Debt to EBITDAi净债务/EBITDA

-0.67

健康

净债务 = $-3.51B

EBITDA (TTM) = $5.27B

Debt Service Coveragei偿债覆盖率

328.73

健康

经营现金流 (TTM) = $4.24B

债务偿付 = $0.01B

V

价值指标

Goodwill %i商誉占比

4.1%

健康

商誉 = $1.09B

总资产 = $26.48B

Working Capital Ratioi营运资本比率

0.30

健康

营运资本 = $7.85B

总资产 = $26.48B

现金流瀑布图

加载图表中...

流入

流出

小计

起止点

C

现金流指标

经营现金流 TTMi

$4.24B

自由现金流 TTMi

$3.71B

FCF = OCF - CapEx

经营现金流 (TTM) = $4.24B

资本支出 (TTM) = $-0.53B

自由现金流收益率i

3.44%

关注

FCF (TTM) = $3.71B

市值 = $107.83B

经营现金流/销售比i

34.60%

健康

经营现金流 (TTM) = $4.24B

营业收入 (TTM) = $12.26B

Q

质量与覆盖指标

收益质量i

0.98x

关注

经营现金流 (TTM) = $4.24B

净利润 (TTM) = $4.34B

现金流/债务比i

2.13x

健康

经营现金流 (TTM) = $4.24B

总负债 = $1.99B

短期覆盖率i

1.09x

健康

经营现金流 (TTM) = $4.24B

流动负债 = $3.88B

资本支出覆盖率i

8.00x

健康

经营现金流 (TTM) = $4.24B

资本支出 (TTM) = $0.53B

E

效率指标

⚡ 比率按USD计算，去除汇率影响

自由/经营现金流比i

87.49%

健康

自由现金流 (TTM) = $3.71B

经营现金流 (TTM) = $4.24B

资本支出/营收比i

4.33%

健康

资本支出 (TTM) = $0.53B

营业收入 (TTM) = $12.26B

净债务/EBITDAi

-0.67

健康

净债务 = $-3.51B

EBITDA (TTM) = $5.27B

G

增长指标

经营现金流增长率i

74.39%

健康

当期OCF (TTM) = $1.43B

上期OCF = $0.82B

股东盈余i

$4.03B

健康

净利润 (TTM) = $4.34B

+ 折旧摊销 (TTM) = $0.22B

- 资本支出 (TTM) = $-0.53B